Aquestive Therapeutics (AQST) Gross Margin (2017 - 2026)
Aquestive Therapeutics' (AQST) quarterly Gross Margin came in at 93.26% in Q1 2026, up 3515.0% year-on-year from 2.58% in Q1 2025, and up 20.84% quarter-over-quarter from 77.18% in Q4 2025.
Aquestive Therapeutics (AQST) Gross Margin (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 93.26% for Q1 2026.
- On a quarterly basis, Gross Margin rose 3515.0% year-over-year to 93.26% in Q1 2026; TTM through Mar 2026 was 147.15%, a 5001.0% increase from a year earlier, with the FY2025 full-year figure at 511.62%, down 60214.0% from the prior year.
- Gross Margin improved to 93.26% in Q1 2026 per AQST's latest filing, from 77.18% in the prior quarter.
- Across five years, Gross Margin topped out at 166.51% in Q4 2024 and bottomed at 34.48% in Q2 2022.
- The 5-year median for Gross Margin is 77.18% (2025), against an average of 79.11%.
- Across the five-year window, Gross Margin surged 15778 bps in 2022 and plunged 8934 bps in 2025, its largest moves.
- Year by year, Gross Margin stood at 50.34% in 2022, then advanced by 16 bps to 58.49% in 2023, then soared by 185 bps to 166.51% in 2024, then sank by 54 bps to 77.18% in 2025, then increased by 21 bps to 93.26% in 2026.
- Per Business Quant, the three latest AQST Gross Margin figures stand at 93.26% (Q1 2026), 77.18% (Q4 2025), and 88.81% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Aquestive Therapeutics | 462.24 Mn | 462.24 Mn | 13.47 Mn | 93.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.26% |
| Dec 31, 2025 | 77.18% |
| Sep 30, 2025 | 88.81% |
| Jun 30, 2025 | 85.66% |
| Mar 31, 2025 | 58.12% |
| Dec 31, 2024 | 166.51% |
| Sep 30, 2024 | 67.24% |
| Jun 30, 2024 | 93.24% |
| Mar 31, 2024 | 88.73% |
| Dec 31, 2023 | 58.49% |
| Sep 30, 2023 | 100.00% |
| Jun 30, 2023 | 100.00% |
| Mar 31, 2023 | 57.45% |
| Dec 31, 2022 | 50.34% |
| Sep 30, 2022 | 59.65% |
| Jun 30, 2022 | 34.48% |
| Mar 31, 2022 | 65.66% |
| Dec 31, 2021 | 69.62% |
| Sep 30, 2021 | 66.88% |
| Jun 30, 2021 | -123.30% |